Mythin 500mcg/75mg Tablet
By Mythin
Rx
10 Tablet in a Strip

Composition
Methylcobalamin(500mcg) + Pregabalin(75mg)

Manufacturer - Seven Hills Life Sciences
H.NO. 5-4-1684, I FLOOR, SAHEB NAGAR SUSHMA SAINAGAR COLONY, VANASTHALIPURAM HYDERABAD TG 500070 IN , - , .

Expires on or after
October, 2025

liver
When it comes to the safety of using Mythin 500mcg/75mg Tablet for patients with liver disease, the limited data currently available indicates that it is likely safe for use. It appears that there may not be a need for dose adjustments in these individuals. However, it is always important to consult with your doctor before starting or continuing any medication, including Mythin 500mcg/75mg Tablet, especially if you have liver issues. Your doctor will be able to provide proper guidance tailored to your specific situation.

kidney
Caution should be observed when using Mythin 500mcg/75mg Tablet in patients with kidney disease, as dose adjustment may be necessary. It is advised to consult your doctor before taking this medication.

alcohol
Mythin 500mcg/75mg Tablet can lead to increased drowsiness when combined with alcohol.

driving
When taking Mythin 500mcg/75mg Tablet, be cautious while driving as it may reduce alertness, cause dizziness, and affect vision. Avoid driving if you experience these symptoms.

pregnancy
Mythin 500mcg/75mg Tablet may not be safe to use during pregnancy due to potential harm to the developing baby, as shown in animal studies. Your doctor will assess the benefits and risks before prescribing this medication. It is important to consult your doctor.

breastfeeding
Mythin 500mcg/75mg Tablet is likely unsafe during breastfeeding, as it may pass into breast milk and harm the baby. It is better to consult your doctor before using Mythin 500mcg/75mg Tablet.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | NEURO CNS |
Action Class | - |
₹90
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 11-Feb-2025